BRP Peptide Australia: Research Overview

The short answer

BRP is short for BRINP2-related peptide, a small 12 amino acid peptide fragment identified by Stanford University researchers using a machine-learning screen and reported in the journal Nature in 2025. In published animal studies it has been investigated for its effect on food intake through an appetite-signalling pathway in the brain. All of the evidence to date is preclinical, meaning it has been studied in laboratory animals such as mice and pigs, not in established human trials.

In Australia, BRP is not an approved therapeutic good. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not an established, approved medicine. It is handled as an unapproved research compound supplied for laboratory research use only. Researchers should check the current TGA Poisons Standard and relevant guidance for the status that applies to their specific work.

What is BRP?

BRP stands for BRINP2-related peptide. It is a short peptide of 12 amino acids that corresponds to a fragment of a larger precursor protein called BRINP2. The idea behind BRP is that the body naturally cleaves, or cuts, smaller active peptides out of larger precursor proteins. BRP is one such predicted fragment.

The peptide was identified as part of a computational and laboratory discovery effort rather than by chance. Researchers built a prediction program that scanned many human precursor proteins and flagged fragments that might act on the brain. BRP was one of the candidates that moved forward into animal testing. It is important to frame BRP as a research-stage molecule and not as a finished medicine.

Quick identity facts

• Name: BRINP2-related peptide, abbreviated BRP
• Size: a short peptide of 12 amino acids
• Origin: a predicted fragment of the larger BRINP2 precursor protein
• Discovery route: an AI and laboratory screen of human peptides, reported in Nature in 2025
• Status: preclinical research compound, studied in animals only

How BRP was discovered

BRP came out of a Stanford University research project led by scientists including Laetitia Coassolo, with Katrin Svensson as senior author. The team built a machine-learning tool, described in the published work as a peptide prediction program, to search for fragments that the body might cut from larger prohormone and precursor proteins. The goal was to find natural peptides that could influence brain pathways involved in appetite.

From a large pool of candidate proteins, the program narrowed the field to a smaller set of peptides for laboratory screening. BRP was among the fragments selected for closer study. The findings were published in the journal Nature in 2025. This is a useful example of how computational screening and wet-lab testing are increasingly combined in peptide discovery.

BRP is best understood as an early discovery from AI-assisted peptide screening, not as an established or approved medicine.

How BRP is reported to work (in neutral terms)

In the published animal research, BRP was investigated for its effect on appetite signalling in the brain. The reported mechanism is described as acting on the central melanocortin system, a network of neurons in a brain region called the hypothalamus that is involved in regulating food intake. In the animal data the peptide was associated with activation of certain appetite-related neurons and downstream signalling markers.

A point the researchers emphasise is that BRP appears to work through a pathway that is distinct from GLP-1 based compounds. According to the published work, in the animal models studied BRP acted independently of the GLP-1 receptor, the leptin pathway and the melanocortin 4 receptor, while still engaging appetite-related neurons centrally. This makes it a different class of candidate from the incretin-based molecules that are widely discussed in the weight-management field.

Mechanism points from the preclinical literature

• Studied for effects on food intake in animal models, not humans
• Reported to act centrally in the hypothalamus on appetite-related neurons
• Described as engaging the central melanocortin system
• Reported in animal studies to act independently of the GLP-1 receptor, leptin and the melanocortin 4 receptor
• A different mechanistic class from incretin or GLP-1 based compounds

Development and trial stage

BRP is at a very early stage of development. The evidence available in the published literature is preclinical, based on studies in laboratory animals including mice and pigs. Early-stage animal research is an important first step, but it does not establish safety, dosing or effectiveness in people, and many compounds that look promising in animals do not progress.

Public reporting around the Stanford work has mentioned intentions to pursue human clinical development in the future, and the senior researcher has been linked to commercialisation efforts. However, we are not stating any specific company, trial registration, trial number or timeline as established fact. As a neutral summary, no completed or established human trial data for BRP is on the public record in the form of a recognised result set. Readers should treat any claim of human results with caution and check primary sources.

Australian regulatory status

BRP is not an approved therapeutic good in Australia. It is not listed on the Australian Register of Therapeutic Goods (ARTG), and there is no established approval for it as a medicine. Because it is an early-stage research compound, it is treated as an unapproved substance and is supplied for laboratory research use only.

The exact scheduling position of a novel research peptide can be uncertain, and classifications can change. The responsible approach is to treat BRP as not approved for therapeutic use in Australia and as research-use-only, and to check the current TGA Poisons Standard and relevant TGA guidance for the status that applies. Researchers and institutions are responsible for ensuring their handling and use complies with all applicable Australian laws and ethics requirements.

How NovaPeptides supplies BRP

NovaPeptides supplies BRP strictly as a research-use-only compound for laboratory research. We do not provide human dosing information, treatment protocols or medical advice, and we make no therapeutic or efficacy claims about BRP. If the compound is listed, it is intended for qualified researchers handling it under appropriate laboratory conditions.

What our research-use-only supply means

• Supplied for laboratory research use only, not for human or animal consumption
• Accompanied by an independent Novagen certificate of analysis where available
• Ships within Australia from our Gold Coast base
• No medical claims, no human dosing guidance and no treatment protocols provided
• Research enquiries can be made via WhatsApp

If you are a researcher and have questions about availability, purity documentation or handling, you are welcome to contact us for research-focused information only.

Putting BRP in context

BRP has attracted growing search interest because it emerged from a high-profile AI-assisted discovery project and because appetite biology is a very active research field. That interest is understandable, but it is worth separating the early-stage science from the way some coverage frames it. At present BRP is a preclinical research molecule, and the honest position is that its relevance to people remains unestablished.

For anyone following this space, the most reliable approach is to read the primary published research, note that the data is from animal models, and avoid drawing conclusions about human outcomes. Regulatory status and the body of evidence may both change over time, so current primary sources and TGA guidance should always take priority over secondary summaries.

Frequently asked questions